The reporter was informed that in the Tianjin Health Industry International Cooperation Demonstration Zone in Jinghai District, Tianjin Hospital of Peking Union Medical College (Phase I) - Tuanbo Campus of the Blood Disease Hospital of the Chinese Academy of Medical Sciences has been officially opened, as the only first-class blood disease hospital in the country, with the deepening of the Beijing-Tianjin-Hebei integration policy, more high-quality medical resources have converged in Tianjin, and the hospital also needs to face the growing demand for patients from the region and even the whole country.
For the hospital's innovative and professional** disease, multiple myeloma, through early diagnosis and early management, accurate prognosis assessment and risk stratification can be achieved**. According to Qiu Lugui, director of the lymphoma diagnosis and treatment center of the Blood Disease Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences, the Institute of Blood Research is the world's largest blood disease hospital, and accurate diagnosis is the characteristic of our hematology. "In the past, Chinese patients did not have the opportunity to receive new drugs**, but now it will be more convenient, and some drugs will be in clinical trials abroad and at home at the same time, so that many patients can use the new drugs in the same way as abroad. ”。
An Gang, chief physician of the Blood Disease Hospital (Institute of Hematology) of the Chinese Academy of Medical Sciences, said that the hardware conditions of the Tuanbo Hospital in Jinghai District are better and there are more beds. "We are an innovative hospital, and a very important task is to promote the listing of new drugs, such as the listing of new drugs, we must do clinical trials, we now have a lot of clinical trials of new drugs, as well as our own researchers to discover clinical trials, to promote the new drug to the market, or to expand its indications, which is also a very important task of our hospital. "With the advent of the era of immunity, the three ways of monoclonal antibodies, bispecific antibodies and CAR-T may achieve multiple myeloma in the future, but how to combine these three in the future is something that needs to be further explored in the future.
It is reported that the Blood Disease Hospital of the Chinese Academy of Medical Sciences is the birthplace of hematology in China, and in the future long-term planning, the Tuanbo Hospital of Jinghai District will focus on malignant hematological tumors to create an international benchmark for high-level clinical diagnosis and treatment, and serve many patients with hematological diseases.